Introgen Therapeutics (INGN) Reorganizes Operations to Focus on Near-Term Sales; Cuts Staff from 45 to 15 Employees
Introgen Therapeutics, Inc. (NASDAQ: INGN) today announced that it has strategically reorganized the company's operations to focus on the expansion of near-term revenues from its manufacturing and service business, Introgen Technical Services, Inc.
In conjunction with the reorganization, David Nance resigned his position as President and CEO. J. David Enloe, Jr. has been named President and CEO of the company, succeeding Mr. Nance, who will continue in his role as chairman of the board.
As part of the restructuring, Introgen will reduce its staff from approximately 45 to 15 employees, significantly lowering corporate expenses. Further, Introgen intends to redirect internal efforts toward its priority objectives of conserving financial resources, expanding revenues and continuing to pursue strategic transactions.
Introgen Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted molecular therapies for the treatment of cancer and other diseases.
In conjunction with the reorganization, David Nance resigned his position as President and CEO. J. David Enloe, Jr. has been named President and CEO of the company, succeeding Mr. Nance, who will continue in his role as chairman of the board.
As part of the restructuring, Introgen will reduce its staff from approximately 45 to 15 employees, significantly lowering corporate expenses. Further, Introgen intends to redirect internal efforts toward its priority objectives of conserving financial resources, expanding revenues and continuing to pursue strategic transactions.
Introgen Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted molecular therapies for the treatment of cancer and other diseases.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
- Canaccord Genuity Morning Coffee on Cree (CREE) and Extreme Networks (EXTR): Shedding Some Light On The Situation
Create E-mail Alert Related Categories
Corporate News, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
